- Remove All
- Your shopping cart is currently empty
CCR4 antagonist 3-1 is a less active chemokine receptor 4 (CCR4) antagonist that inhibits [125I]TARC (thymus and activation-regulated chemokine) with an IC50 value of 1.7 μM. CCR4 antagonist 3-1 inhibits the binding of radiolabeled [125I]TARC and macrophage-derived chemokine ( MDC) to CEM cell surface and inhibits TARC-mediated CEM cell migration in vitro with an IC50 value of 6.4 μM. CCR4 antagonist 3 inhibited the binding of radiolabeled [125I]TARC and macrophage-derived chemokine (MDC) to the CCR4 receptor on the surface of CEM cells and inhibited TARC-mediated migration of CEM cells in vitro with an IC50 value of 6.4 μM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $93 | In Stock | |
5 mg | $228 | In Stock | |
10 mg | $372 | In Stock | |
25 mg | $728 | In Stock | |
50 mg | $1,130 | In Stock | |
100 mg | $1,530 | In Stock | |
500 mg | $2,970 | In Stock |
Description | CCR4 antagonist 3-1 is a less active chemokine receptor 4 (CCR4) antagonist that inhibits [125I]TARC (thymus and activation-regulated chemokine) with an IC50 value of 1.7 μM. CCR4 antagonist 3-1 inhibits the binding of radiolabeled [125I]TARC and macrophage-derived chemokine ( MDC) to CEM cell surface and inhibits TARC-mediated CEM cell migration in vitro with an IC50 value of 6.4 μM. CCR4 antagonist 3 inhibited the binding of radiolabeled [125I]TARC and macrophage-derived chemokine (MDC) to the CCR4 receptor on the surface of CEM cells and inhibited TARC-mediated migration of CEM cells in vitro with an IC50 value of 6.4 μM. |
In vivo | CCR4 antagonist 3-1 (compound 1) (0.5 mg/kg, i.v.; 2 mg/kg, p.o.; single dosage) exhibited a high clearance of 4.2 L/h/kg a short half-life of 0.4 h, and the oral bioavailability of 2%.[1] |
Molecular Weight | 240.32 |
Formula | C14H12N2S |
Cas No. | 1957-01-3 |
Smiles | N(C=1C2=C(C=CC1)C=CC=C2)C3=NC(C)=CS3 |
Storage | store at low temperature | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45 mg/mL (187.25 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.